Bausch Health(BHC) - 2024 Q1 - Quarterly Results

Exhibit 99.1 CH-Health "We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan®, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb. • RED-C: prevention and delay of first episode of hepatic encephalopathy ◦ Enrollment of the second global Phase 3 trial completed in April 2024. Enrollment of both global Phase 3 studies are now complete and currently in ...